Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation
| العنوان: | Efficacy of Semaglutide in a Subcutaneous and an Oral Formulation |
|---|---|
| المؤلفون: | Juris J. Meier |
| المصدر: | Frontiers in Endocrinology, Vol 12 (2021) Frontiers in Endocrinology |
| بيانات النشر: | Frontiers Media S.A., 2021. |
| سنة النشر: | 2021 |
| مصطلحات موضوعية: | 030213 general clinical medicine, Endocrinology, Diabetes and Metabolism, Injections, Subcutaneous, efficacy, Glucagon-Like Peptides, Administration, Oral, 030209 endocrinology & metabolism, Review, Pharmacology, Glucagon-Like Peptide-1 Receptor, Diseases of the endocrine glands. Clinical endocrinology, 03 medical and health sciences, body weight, oral, 0302 clinical medicine, Endocrinology, glycated hemoglobin (HbA1c), medicine, Empagliflozin, Humans, Hypoglycemic Agents, Insulin, Canagliflozin, Glycated Hemoglobin, semaglutide, Insulin glargine, Liraglutide, business.industry, Semaglutide, RC648-665, glucagon-like peptide-1 receptor agonist (GLP-1RA), Diet, Exercise Therapy, Treatment Outcome, Clinical Trials, Phase III as Topic, Diabetes Mellitus, Type 2, Research Design, Sitagliptin, Quality of Life, Dulaglutide, subcutaneous, type 2 diabetes, business, Exenatide, medicine.drug |
| الوصف: | Despite the benefits of early and effective glycemic control in the management of type 2 diabetes (T2D), achieving glycated hemoglobin (HbA1c) targets is challenging in some patients. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) provide effective reductions in HbA1cand body weight. Semaglutide is the only GLP-1RA that is available in both an injectable and oral formulation. The efficacy of once-weekly subcutaneous semaglutide and once-daily oral semaglutide has been investigated in the global SUSTAIN and PIONEER phase III clinical trial programs in a range of clinical settings, including early T2D managed with diet and exercise only, more established T2D uncontrolled on one to three oral antidiabetic drugs, and advanced disease treated with insulin. Across the SUSTAIN program, once-weekly subcutaneous semaglutide 1.0 mg reduced HbA1cby 1.5–1.8% after 30–56 weeks, which was significantly more than sitagliptin, liraglutide, exenatide extended release, dulaglutide, canagliflozin, or insulin glargine. Across the PIONEER program, once-daily oral semaglutide 14 mg reduced HbA1cby 1.0–1.4%, significantly more than sitagliptin or empagliflozin, and to a similar extent as liraglutide after 26 weeks. In addition, subcutaneous semaglutide reduced body weight significantly more than all active comparators tested, while oral semaglutide reduced body weight more than sitagliptin and liraglutide, and to a similar extent as empagliflozin. Neither formulation of semaglutide has been associated with an increased risk of hypoglycemia and both improve various measures of health-related quality of life. Semaglutide offers the benefits of a highly effective GLP-1RA in both injectable and oral formulations. Selection of the most appropriate formulation can be made on an individual basis to best suit the patient’s preferences and needs. |
| اللغة: | English |
| تدمد: | 1664-2392 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5701b067c851c878a8cc55b425ac7f47Test https://www.frontiersin.org/articles/10.3389/fendo.2021.645617/fullTest |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....5701b067c851c878a8cc55b425ac7f47 |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16642392 |
|---|